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ABSTRACT 
Colon cancer is the fourth most common cancer globally with 639,000 deaths reported annually. 
Typical chemotherapy is provided by injection route to reduce tumour growth and metastasis. 
Recent research investigates the oral delivery profiles of chemotherapeutic agents. In comparison to 
injection, oral administration of drugs in the form of a colon-specific delivery system is expected to 
increase drug bioavailability at target site, reduce drug dose and systemic adverse effects. Pectin is 
suitable for use as colon-specific drug delivery vehicle as it is selectively digested by colonic 
microflora to release drug with minimal degradation in upper gastrointestinal tract. The present 
review examines the physicochemical attributes of formulation needed to retard drug release of 
pectin matrix prior to its arrival at colon, and evaluate the therapeutic value of pectin matrix in 
association with colon cancer. The review suggests that multi-particulate calcium pectinate matrix 
is an ideal carrier to orally deliver drugs for site-specific treatment of colon cancer as 1. 
crosslinking of pectin by calcium ions in a matrix negates drug release in upper gastrointestinal 
tract, 2. multi-particulate carrier has a slower transit and a higher contact time for drug action in 
colon than single-unit dosage form, and 3. both pectin and calcium have an indication to reduce the 
severity of colon cancer from the implication of diet and molecular biology studies. Pectin matrix 
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COLON ANATOMY AND PHYSIOLOGY 
The term colon refers to the lower part of gastrointestinal tract, extending from ileocecal junction to 
anus (Fig. 1). It is divided into several sections, i.e. cecum, ascending colon, transverse colon, 
descending colon, sigmoid colon and rectum with characteristic lengths of 6 to 7, 20, 45, 30, 40 and 
12 cm respectively and an average internal diameter of 6 cm (1,2). The main role of colon is 
consolidation of intestinal content into feces by absorption of water and electrolytes. The colon has 
a large absorptive capacity of which 2000 ml of fluid entering the colon each day will be absorbed 
by more than 90 % (1). In healthy human subjects, sodium and chloride ions are usually absorbed 
and potassium and bicarbonate ions are usually secreted. Fluid and electrolyte absorption is assisted 
by segmental contraction which circulates chyme across colonic mucosa. 
 
The colon epithelium is covered and protected by mucus of which the major glycoprotein 
constituents are mucins (3). Two structurally and functionally distinct classes of mucins have been 
identified: secreted gel-forming mucins (MUC2, MUC5AC, MUC5B and MUC6) and 
transmembrane mucins (MUC1, MUC3A, MUC3B, MUC4, MUC12 and MUC17). The mucins 
contain a high content of carbohydrates which are present in the form of clustered oligosaccharides 
linked to tandem repeat peptides rich in threonine, serine and proline. They possess a high 
molecular weight, are resistant to degradation in intestinal tract and recognizable by a number of 
antibodies and lectins.  
 
The colon contains an almost neutral and reducing medium. In healthy human subjects, the part of 
gastrointestinal tract which exhibits the highest pH level is terminal ileum (7.5 ± 0.5) (1). On the 
contrary in the colon, pH is reduced to 6.4 ± 0.6, 6.6 ± 0.8 and 7.0 ± 0.7 at proximal, middle and 
distal colon regions respectively (1,2,4). Under normal physiological condition of healthy human 
subjects, the colon exhibits irregular alternation of quiescence, non-propagating, segmental 
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contractions and far less frequent propagated contractions (5). While segmental and propagated 
contractions predominate in mid-region and distal colon respectively, retrograde movements have 
been demonstrated at proximal colon and contribute to increase mass retention in ascending colon 
and cecum thereby promoting fermentation, electrolyte and water resorption (1). 
 
A dosage form that does not undergo disintegration/dissolution in the upper gastrointestinal tract 
could require 4 to 12 hours to reach colon following oral administration (1). In comparison to upper 
gastrointestinal tract, the transit of chyme through colon is slower and the total transit time is highly 
variable and affected by several factors. Under normal condition, the mean total colonic transit time 
is 35 hours as indicated by radiopaque marker technique. The mean segmental transit times of right 
(ascending and part of transverse), left (part of transverse and descending) and rectosigmoid colon 
are 11.3, 11.4 and 12.4 hours respectively. The total colonic transit time is shorter in male than 
female. Smaller dosage forms such as microparticulate systems (granules, pellets, beads), travel at a 
slower rate in colon than larger units (tablets) unlike gastric emptying profile of the same dosage 
forms (1-4). The transit rate of colonic content does not exceed the doubling time of bacteria (6). 
The bacteria can proliferate and ferment the chyme along its colonic passage. 
 
COLONIC MICROFLORA 
The human colon consists of over 400 distinct species of bacteria with a population of 1011 to 1012 
CFU/ml and a small number of fungi (1,2,5,6). A breakdown of microbial count with respect to 
aerobic or facultative bacteria, fungi and anaerobic bacteria is summarized in a review by 
Vandamme et al. (2). In a healthy adult, the microbial community consists of autochthonous and 
allochthonous microbes (6). The main species include Bacteroides, Bifidobacterium, Eubacterium 
and Lactobacillus (2,5,6,7). These bacteria produce reductive and hydrolytic enzymes which are 
active in carbohydrate and protein fermentation, bile acid and steroid transformation and 
  5 
metabolism of xenobiotic substances (5). The proximal colon has the highest rate of microbial 
growth as it receives the highest concentration of energy source (1). The primary source of nutrition 
for these anaerobic bacteria is carbohydrates such as non-starch polysaccharides from the intestinal 
chyme (5). The non-starch polysaccharides are fermented during transit through colon via 
enzymatic action of α-L-arabinofunosidase, β-D-fucosidase, β-D-galactosidase, β-D-glucosidase 
and β-xylosidase (5,6). Polysaccharide enzymatic breakdown is greater in proximal colon than 
distal colon, while is negligible in stomach and small intestine (1,5).  
 
The end products of fermentation include short chain fatty acid, carbon dioxide, hydrogen, methane 
and hydrogen sulphide (1). The highest level of short chain fatty acid is produced at right colon 
(127 mM) with a molar ratio distribution of 57:22:21 for acetate, propionate and butyrate 
respectively (2). The total short chain fatty acid concentrations at transverse and left colon are 117 
and 90 mM respectively, with corresponding molar ratio distributions of 55:22:23 and 57:21:22 for 
acetate, propionate and butyrate. The short chain fatty acids are responsible for the pH lowering 
observed in colon, nonetheless they are rapidly absorbed from large intestine stimulating at the 
same time sodium and water absorption (6). The fatty acids are utilized as energy source of 
intestinal epithelium. The butyrate in addition regulates nucleic acid metabolism of epithelial cells 
and maintains the health of epithelium. In human, the composition of colonic bacteria population 
and enzymes levels are influenced by age, diet, geographic prevalent, intestinal pH, motility and 




Colon is liable to a number of pathological conditions, namely infections, inflammatory bowel 
diseases (Crohn’s disease and ulcerative colitis), irritable bowel syndrome and cancer. Colon 
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cancer, commonly known as colorectal cancer or large bowel cancer refers to cancerous growth in 
colon, rectum or cecum. A total of 639,000 deaths related to colon cancer are reported worldwide 
each year (8). Colon cancer is the fourth most common form of cancer globally. Colon cancer is 
reckoned to be a disease of affluence, as it occurs most frequently in North America, Australia, 
New Zealand, Japan and Western Europe (9-12). 
 
It is generally accepted that colon cancer is mainly attributable to diet in one way or another 
(9,11,13). Several additional risk factors have been related to colon cancer, including gender and 
ethnicity with a higher risk in male than female and black than white respectively (9-11,14), old age 
(10,11,13), presence of adenomatous polyps (10,11,13), previous history of ovary, uterus or breast 
cancer (15), smoking and alcohol drinking habits (9,10,16), physical inactivity (9,11), contraction of 
specific strains of human papilloma viral infection (15), Streptococcus bovis bacteremia and 
inflammatory bowel diseases (10,11,13), particularly ulcerative colitis. Administration of 
exogenous hormones such as estrogen in hormone replacement therapy, as well as, regular use of 
non-steroidal anti-inflammatory drugs, are reported to exert some protective effects against colon 
cancer (9-11,17,18). 
 
Sixty to eighty percent of colon cancer cases do not appear to be attributed to inherited symptoms or 
familial tendency, and are known as sporadic cancer (19). The risk of developing sporadic colon 
cancer is significantly modulated by environmental factors. The majority of sporadic colon cancer 
manifests via tumour suppressor/chromosomal instability pathway which could involve the 
mutation/loss of APC (adenomatous polyposis coli), p53, DCC (deleted in colonic cancer), SMAD 4 
and K-ras genes, as well as, activation of telomerase (Fig. 2) (10,18-21). Ten to fifteen percent of 
sporadic colon cancer express via microsatellite pathway which involves mutation of MMR 
(mismatch repair) genes (10,19). Ninety five percent of all malignant tumours of colon are 
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carcinomas (22). Early colon carcinomas are limited to submucosa as polypoid lesion, 
pedunculated, semipedunculated or sessile (14,22). Flat lesion with no or slight elevation of not 
more than twice the mucosa height can exist possibly with slight central depression. Advanced 
carcinoma invades beyond submucosa and is frequently found ulcerated with sharply demarcated 
margin or to a lesser extent as polypoid. Adenocarcinoma and mucinous adenocarcinoma represent 
90 to 95 % of carcinomas. Some adenocarcinomas produce abundant mucus. These carcinomas 
remain as adenocarcinomas unless mucus contributes to more than 50 % of tumour bulk. The 
severity of carcinoma is indicated by histopathological grading G1 to G4 which ranges from well 
differentiated carcinoma with cellular features closely resemble to normal epithelium to 
undifferentiated carcinoma with no glandular and squamous differentiation at all. The anatomical 
extent of colon carcinoma is described by Dukes classification where A, B and C denote tumour 
invading submucosa, muscularis and lymph node respectively, and D denotes distant metastasis or 
TNM (Tumour Node Metastasis) system with T grades the level of tumour invasiveness, N grades 
the involvement of regional lymph node and M grades the level of distant metastasis (11,13,21).  
Surgery remains the primary mode of colon cancer treatment with chemotherapy and/or 
radiotherapy recommended upon the nature and extent of severity of disease. Chemotherapy can be 
provided after surgery as adjuvant, before surgery as neo-adjuvant or as primary therapy to reduce 
tumour size and growth as well as the likelihood or propensity of metastasis. Chemotherapy is given 
as adjuvant when the cancer has spread to lymph nodes. Typical regimen of adjuvant chemotherapy 
is based on the combination infusion of 5-fluorouracil, leucovorin and oxaliplatin (11). In case of 
metastasis, the chemotherapy is given as a primary treatment and is represented by a combination of 
infusional 5-fluorouracil, leucovorin and oxaliplatin with bevacizumab or 5-fluorouracil, leucovorin 
and irinotecan with bevacizumab (15,23,24). The majority of metastases arising from colon cancer 
is confined to liver (11). Regional delivery of chemotherapy can be performed via hepatic artery, as 
this has been known for years to supply blood to micrometastasis (25). 
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Alternatively, the chemotherapeutic agents can be administered via the oral route. Many oral 
chemotherapeutic agents, mainly fluorinated pyrimidines, have been developed and evaluated for 
the treatment of advanced and curatively resected colon cancer (26). In comparison to injection, oral 
administration of anti-cancer agents is expected to improve the quality of life of patients and 
increase the cost-effectiveness of treatment through reducing the duration of hospitalization. 
Possible examples of these anti-cancer agents are 5-fluorouracil, hexycarbamoyl-5-fluorouracil 
(carmofur), uracil/tegafur, uracil/tegafur/leucovorin and N4-pentoxylcarbonyl-5’-deoxy-5-
fluorocytidine (capecitabine) (11,24,26). Oral administration of uracil-tegafur with leucovorin or 
capecitabine demonstrates approximately equal efficacy and similar median survival time, but less 
mucositis, neutropenia and alopecia than intra-venous 5-fluorouracil (11,24). Various positive 
clinical outcomes on usage of oral chemotherapeutic agents for treatment of colon cancer have been 
reviewed by Sakamoto et al. (26). The transformation of injectable to oral route is deemed to be a 
feasible approach in drug administration. Indeed, the orally administered capecitabine has been 
recommended clinically as an equivalent alternative to intravenously administered 5-fluorouracil-
leucovorin (27). 
 
COLON-SPECIFIC ORAL DRUG DELIVERY SYSTEM 
With respect to the treatment of colon cancer by orally administered chemotherapeutic agents, it has 
been suggested by several authors that if the drug is released from the dosage form specifically in 
the colonic region, it can achieve maximal pharmacological effect. Indeed, colon targeted drug 
delivery can increase drug bioavailability at target site, possibly allowing for the reduction of the 
administered dose and decrease of systemic side effects (4,6). Delivering the drug specifically to the 
colon is ideal for the exploitation of new biotechnology drugs, such as peptides or protein drugs, 
due to minimized acidic and enzymatic drug degradation otherwise predominant in the upper 
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gastrointestinal tract. The degree of drug absorption can be enhanced by exploiting the greater colon 
susceptibility to absorption enhancer effects and prolonged dosage form transit time in comparison 
to upper gastrointestinal tract (28). However, to succeed in colon targeting it is imperative to deliver 
drugs at adequate local concentration and without premature drug release/loss in the upper 
gastrointestinal tract. 
 
Broadly, five colon-specific drug delivery technologies have been developed and evaluated for their 
suitability over the years. They all have a common key concept of exploiting unique physiological 
features of the gastrointestinal tract to obtain system activation and drug release only upon reaching 
the colonic region. They are prodrug/azo-polymer systems, time-dependent systems, pH-dependent 
systems, pressure-dependent systems and microbial triggered systems (1,2,4,6,29,30).  
 
Azo-polymers are relatively stable in upper gastrointestinal tract. The azo bonds can resist chemical 
and enzymatic actions in stomach and small intestine. Nevertheless, the hydrophobic azo-polymers 
undergo slow degradation by enterobacteria making the intended drug release at specific site 
delayed (31). However, a risk has been evidenced that azo-polymeric matrices degradation results 
in the formation of toxic by-products, making such systems unsuitable for long-term treatments. 
The prodrug approach, on the other hand, is restricted by the availability of functional groups on 
drug moiety for chemical linkage and new drug entity requiring lengthy evaluation from a 
regulatory point of view prior to its use in market.  
 
pH-dependent systems are commonly formulated using enteric coating techniques (32). However, 
the small intestine and large intestine do not have a markedly different pH environment and, as a 
consequence, the reproducibility of drug release at a well-defined site from a pH-dependent system 
can be poor. In other words, the use of enteric coated dosage form may be accompanied by 
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premature drug release in the small intestine. This depends also on the profile of gastrointestinal 
motility which varies among individuals and disease/dietary conditions which lead to variations in 
pH of intestine. 
 
In a similar way, changes in motility, pH and microflora activity of the gastrointestinal tract affect 
the site specificity of time-dependent systems. Time-dependent systems exploit gastro-intestinal 
transit time as a tool to tune drug delivery to the colon by means of a suitably delayed release 
profile (33). It is practically difficult to utilize transit time as a measure to target drug delivery of 
these systems at colon. The suitability of pressure-dependent systems is a function of the 
reproducibility in pressure and duration of peristaltic waves as well as of disease condition (34). 
The high pressure phases in colon are known to be infrequent and follow circadian rhythm with 
maximum frequency after waking, meals and with defecation. The success rate of drug release from 
a pressure-dependent system in colon is therefore low or unpredictable. 
Colon-specific drug delivery by means of prodrugs, azo-polymers, time-, pH- and pressure-sensitive 
approaches has respective pros and cons. Each of them encounters limitations in degree of site 
specificity, toxicity, ease of preparation and reproducibility of performance. In comparison to these 
approaches, drug release triggered by colonic microflora is envisaged to have a higher degree of site 
selectivity. Polysaccharides can be selectively degraded by colonic enzymes and their use as drug 
vehicle can trigger drug release to start in the colon. The degradation of polysaccharides by 
microflora exhibits a relatively consistent pattern across diverse human population (35), thus 
assuring the reproducibility of drug release performance of polysaccharide-based drug carriers. 
Using naturally occurring dietary polysaccharides, the issues of toxicity and safety are minimized. 
The main saccharolytic species in colon are Bacteroides and Bifidobacterium (6). The success of 
polysaccharides as drug carriers also lies in their ability to hydrate and swell creating a diffusion 
barrier during its gastrointestinal transit. Upon arrival at colon, the hydrated vehicle permits the 
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access of colonic bacteria/enzymes to degrade the polysaccharide network and release the drug at 
the intended site. Examples of polysaccharides which are potentially useful in the formulation of 
colon-specific drug delivery systems include alginate, amylose, arabinogalactan, arabinoxylan, 
cellulose, chitosan, chondroitin sulphate, dextran, guar gum, locust bean gum, inulin, karaya gum, 
laminarin, pectin, starch, tragacanth gum, xanthan gum and xylan (1,2,4,6,29,36).  
 
PECTIN AND COLON CANCER  
Pectin is a natural heteropolysaccharide with at least 65% by weight of galacturonic acid units (37). 
It is made of 1,4 linked α-D-galactosyluronic acid residues and a range of neutral sugars such as 
rhamnose, galactose, arabinose and lesser amounts of others (37,38). Pectin is available in the form 
of free acid, simple salt such as sodium, potassium and calcium salts, methyl ester, acetylester, 
feruloylester or amidated polysaccharide (36,37,39,40). Pectin is polymolecular and polydisperse. It 
contains a few hundreds to about 1000 saccharide units in a chain like configuration, corresponding 
to an average molecular weight between 50000 and 150000 daltons (41). 
Pectin is suitable for use as colon-specific drug delivery vehicle in treatment of colon cancer and 
other colon diseases as it is selectively digested by microflora in colon and exhibits potential to 
prevent colon cancer from the implication of diet (42). Being a soluble dietary fiber, pectin is 
reported to increase the transit time through gastrointestinal tract, fecal bulk, bile acid excretion and 
short chain fatty acid production. Unlike insoluble fiber such as cellulose, it undergoes almost 100 
% fermentation in colon (43). Fermentation of pectin leads to the generation of short chain fatty 
acids (42,43). The short chain fatty acids are the primary energy source of colonocyte (12,43,44). 
Moreover, these fatty acids lower the colonic pH, which is protective against colon cancer 
(42,43,45). In fact, epidemiology studies indicated that colon cancer subjects have a fecal pH of 7, 
whereas normal subjects have a fecal pH of 6.5. 7-α-dehydroxylase is the bacterial enzyme which 
converts primary bile acids into secondary bile acids such as lithocholic acid and deoxycholic acid, 
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known as promoter of colon cancer. Though debatable, the lowering of pH obtained by pectin 
fermentation can reduce the risk of colon cancer by diminishing the production of secondary bile 
salts, via inhibiting the activity of 7-α-dehydroxylase at a pH below 6.5 and by simultaneously 
decreasing free bile acid solubility (43,45). The level of bile acids can be further lowered by pectin 
via increasing their excretion in feces (42,46).  
 
In addition to colonic pH lowering effects, short chain fatty acids decrease colon hyperproliferation 
induced by deoxycholate in association with reduced expression of c-Fos and c-Jun (42). They have 
shown to promote apoptosis in a variety of colon tumour cell lines and are able to depress 
proliferation of tumour cells in vivo (12,42,43). The butyrate induces apoptosis in tumour cells 
which lack a functional p53 pathway via a caspase-dependent process (12). It downregulates bcl-2 
oncogene thereby removes the barrier to apoptotic cell death (16). The butyrate induces histone 
hyperacetylation via the inhibition of histone deacetylase (12,18,43). Acetylation of histone favors 
an open, transcriptionally active chromatin configuration which in turn facilitates the expression of 
pro-apoptotic genes.  
 
While low methoxyl pectin, high methoxyl pectin and citrus pectin are found to increase the risk of 
colon tumour (47,48), apple pectin and citrus pectin have been reported lately to decrease the 
number and incidence of colon tumour (49,50). Pectins and pecticoligosaccharides are found to 
increase the apoptosis frequency of colonic adenocarcinoma cell line HT29 (51). Dietary 
supplementation of pectin indicates that pectin can suppress colon cancer significantly and exert 
anti-proliferative effect in mouse distal colon (52,53). Pectin can negate colon cancer via inhibiting 
galectin-3 biological functions. Galectin-3 is a chimeric gene product with a monomer subunit of 
approximately 30000 daltons which undergoes noncovalent homodimerization (3). It is a β-
galactoside binding protein which can be found in the cytoplasm and nucleus, on the cell surface, 
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and is secreted by tumour cells. Galectin-3 mediates cell-cell adhesion to reduce apoptosis incurred 
by anoikis, and to induce initial adhesion of cancer cells to endothelium and subsequent tumour cell 
homotypic aggregation (Fig. 3) (3,54-56). It promotes tumour cells to interact with extracellular 
matrix proteins in development of a secondary tumour growth, clonogenic survival of cancer cells, 
and stimulates endothelial cell morphogenesis and angiogenesis necessary for tumour growth. 
Specific gene expression and anti-apoptotic activity are regulated by nucleus and cytoplasmic 
galectin-3 respectively, whereas extracellular galectin-3 mediates cell migration, cell adhesion and 
cell-cell interaction through its carbohydrate binding property. Galectin is expressed at higher levels 
in colon cancer than normal colon. It binds to colonic MUC 2 mucin with altered carbohydrate 
structure. Carbohydrate or polysaccharide mediated interference with galectin-3 binding to mucin 
can lead to therapeutic or prevention advantages in colon cancer. Modified citrus pectin, low 
methoxyl pectin and high methoxyl pectin are reported as antagonists to galectin-3 (3,54-58). 
Modified citrus pectin has shown to reduce the growth and metastasis of colon tumour (3,56-58). 
Orally administered modified citrus pectin at 0.8 and 1.6 mg/ml for 20 days to balb-c mice 
implanted with colon-25 tumours exhibits a dose-dependent reduction in tumour size (57). The 
modified citrus pectin has a potential to raise the apoptotic response of tumour cells to 
chemotherapy (56). The summative observation indicates the likelihood of pectin being utilized as 
drug, matrix vehicle and therapeutic sensitizer of anti-cancer agents.  
 
Citrus pectin modified by heat treatment is reported to lead to significant levels of tumour cell 
apoptosis comparable to fractionated pectin powder (56). pH treatment of modified citrus pectin is 
critical to reduce cell-cell adhesion in the development of tumour though it is reported that mild 
base treatment removes ester linkages of pectin  and destroys its apoptotic activity. Pectin exhibits a 
higher strength of mucoadhesion on large intestinal mucosa than small intestinal mucosa (59). The 
mucoadhesion property of pectin is promoted by high degree of esterification and large molecular 
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weight attributes of pectin. High esterified pectin tends to form gel network with endogenous mucin 
on the surfaces of colonic mucosa (60). The strong tendency of pectin to interact with large 
intestinal mucosa is expected to interrupt the biochemical processes mediating cell-cell adhesion in 
tumour growth. Modification or processing of pectin by means of heat or pH treatment shall avoid 
excessive molecular chain breakdown or de-esterification of pectin which can translate to a loss of 
its mucoadhesiveness and therapeutic function. 
 
PECTIN AS COLON-SPECIFIC ORAL DRUG DELIVERY VEHICLE 
Pectin is completely fermented in colon by microflora with low esterified pectin being fermented 
faster than high esterified pectin (61). It appears that only a partial degradation is possible at the pH 
2 to 4 conditions of stomach via side chain hydrolysis and at pH 5 to 6 conditions of small intestine 
via β-elimination of main chain or de-esterification (61,62). Nonetheless, pectin is an aqueous 
soluble polymer. The matrix made of pectin is prone to swelling as well as erosion in aqueous 
medium leading to premature drug release at upper gastrointestinal tract and thereby defeating its 
ability as colon-specific drug delivery vehicle.  
 
The pectin-based matrix is available as single-unit dosage form such as tablet or multiple-unit 
dosage form, namely beads, pellets and microparticles. In designing colon-specific drug delivery 
systems, numerous formulation approaches have been taken in the past years to prevent pectin-
based matrix from undergoing early drug release in the upper gastrointestinal tract (Fig. 4). The 
pectin in matrix has been subjected to crosslinking by di- or multi-valent cations, coacervation with 
an oppositely charged polyelectrolyte, mixing with viscous polymer and/or calcium salt, or coating 
with viscous, pH resistant or poorly water-soluble polymer, coacervate and/or complex to reduce its 
drug dissolution propensity in aqueous medium prior to reaching the colon (Table 1). Pectin, in 
combination with a crosslinking agent or a polymer, may also be employed itself as a delayed-
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release coat to be applied onto a drug core via film or compression coating technique. In particular, 
multiple coat layers can be applied onto the drug core and these coats can vary in their chemical 
composition in order to retard/modulate drug release at different sites of upper gastrointestinal tract. 
Pectin has also been used to prepare prodrugs which will release the free drug upon arrival at colon. 
Table 1 summarizes several types of pectin-based colon-specific dosage forms and their associated 
formulation mechanisms. In addition to the anti-cancer agents 5-fluorouracil and methotrexate, anti-
inflammatory drugs, antibiotics, anti-nociceptive agents and enzymes have been formulated in the 
form of pectin-based matrix for colon delivery. A schematic flowchart in relation to processing 
technology employed in crosslinking, coacervation, compression and coating of various 
formulations is shown in Fig. 5. 
 
The proposed formulation strategies to prevent premature drug release from pectin-based colon-
specific dosage form exploit a number of mechanisms as follow: 
 
1. enhancement of hydrophobicity  
2. reduction of aqueous solubility  
3. enhancement of physical strength  
4. enhancement of viscosity  
5. reduction of swelling capacity 
6. reduction of erosion capacity  
 
of the pectin-based matrix or coat. A functional colon-specific dosage form must not exhibit 
premature drug release at upper gastrointestinal tract. It must nevertheless be able to hydrate, swell 
and absorb enzyme- or microflora-rich fluids in colon. The pectinolytic enzymes would then digest 
the pectin components of matrix or coat of a dosage form thereby initiating drug release.  
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High methoxyl pectin has been advocated as the polymer of choice because it is inherently less 
water soluble than low methoxyl pectin (75,76,86). However, it is reported that low methoxyl 
pectinate beads coated with high methoxyl pectin exhibit a higher propensity of drug release than 
uncoated beads (92). This is ascribed to prolonged exposure of drug core to moist high methoxyl 
pectin layer during coating process. It results in drug migration to the surface and leads to a burst 
release effect upon erosion and dissolution of the high methoxyl pectin coat. Low methoxyl pectin 
is prepared by hydrolytic demethylation of high methoxyl pectin (83). This reaction is known to 
reduce the molecular weight and chain length of pectin. Shorter chain length of pectin is 
characterized by its higher aqueous solubility, unstable polymeric network and faster drug release. 
In conjunction with colon-specific dosage form prepared using chitosan and/or multi-valent cationic 
salt, low methoxyl pectin is nevertheless preferable as it is able to interact with chitosan or cationic 
salt to a greater extent than high methoxyl pectin due to the availability of a higher fraction of free 
carboxylic acid groups.  
 
Crosslinking of pectin with calcium ion or zinc ions, as well as, coacervation/complexation with 
polymers such as chitosan and/or Eudragit decreases the solubility, swelling and erosion extent of 
the polymer, but increases the mechanical strength and hydrophobicity of the dosage form. An 
increase in hydrophobicity of the dosage form due to charge neutralization reduces its tendency to 
interact with dissolution medium thereby lowering the rate and extent of drug release. A reduction 
in solubility, swelling and erosion and an increase in mechanical strength, following complex or 
crosslink formation, minimize the breakdown of dosage form, the generation of surface pore or 
cracks and similarly reduce the abrupt release of drug from dosage form to surrounding dissolution 
medium. The hydrophobicity and drug release retardation capacity of colon-specific dosage form 
can be further promoted by coating the matrix with ethylcellulose, a water-insoluble polymer. The 
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mechanical strength of dosage form can be modulated and enhanced through blending of pectin 
with hydroxypropylmethylcellulose or dextran. The combination with 
hydroxypropylmethylcellulose or dextran can increase the gel viscosity of the hydrated dosage 
form. It reduces the erosion propensity of matrix thereby lowering drug release. 
 
 The chemical composition of the matrix and/or coat polymer is the key parameter affecting the 
drug release pattern of colon-specific dosage form. Sustaining drug release will be less possible 
when calcium pectinate is used instead of pectin to complex with Eudragit (95). The calcium 
pectinate has a lower fraction of carboxylate moiety than pectin as some of its active sites are 
occupied by calcium ions. The level of calcium pectinate-Eudragit complexation is lower than 
that of pectin-Eudragit and the formed complexes are less able to retain drug within the matrix. The 
lowest drug release can be obtained when a coat is made of a high content of pectin complexed to 
chitosan, using low methoxyl pectin and highly deacetylated chitosan which provide a substantial 
fraction of carboxylate and amino moieties respectively for coacervation reaction (96). In any case, 
coacervation of pectin with chitosan however does not negate the drug release of pectin-based 
dosage form in response to pectinolytic enzymes (76,81). 
 
In drug delivery system with coat composed of pectin and hydrophobic polymer, the digestion of 
pectin results in the formation of pores for drug release (72,73,75,85,95). The fraction of 
hydrophobic polymer in the coat must not be excessively high in order for pectin to hydrate for 
enzymatic digestion to take place at colon. It must not be too low as this will bring about premature 
drug release. The optimal pectin content has been reported to constitute less than 20 % in the 
composite (36). In coat made of complex of water-soluble polymers, the action of pectinolytic 
enzymes on the coat complex gives rise to pectin leaching and drug release in colon (86). The 
hydrophilic polymer counterpart of pectin, once released from complex, similarly becomes freely 
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solvated, swells and leads to distortions in coat thereby further facilitating drug release. Enzymatic 
degradation of pectin components forms the primary mechanism of colon-specific drug release. 
Nevertheless, the leaching of pectin components from coat may suppress the formation of hydrated 
pectin channels (87,92). The undigested coat on matrix can be reconstructed via distension, 
plugging up pores, reducing free volume between polymer chains and preventing drug release. The 
restructuring of coat is possible when glass transition temperature of coat is close to temperature of 
dissolution medium and it can be lowered when polymers are placed in a liquid environment. In 
accentuation of drug release from the core to the surrounding colonic medium, a disintegrant such 
as crosslinked polyvinylpyrrolidone can be added to such matrix (72). The digestion of pectin by 
pectinolytic enzymes is accompanied by water influx into core and build-up of pressure by 
crosslinked polyvinylpyrrolidone onto surrounding coat/matrix substances, thus accelerating the 
release of drug in colon. 
 
Calcium ions are commonly used as crosslinking agent in preparation of pectin-based colon-specific 
dosage form. The incorporation of a calcium salt into a pectin matrix enhances the susceptibility of 
pectin to enzymatic digestion in human colon since many pectinases have shown to be stimulated 
by or have an absolute requirement for calcium ions for their activity (36,63,64). The calcium 
pectinate matrix is found to release the major part of drug in intestinal medium (67,69,77). 
Generally, the use of a higher calcium ion content can reduce drug release while the matrix travels 
along the gastrointestinal tract towards colon and it could provide sigmoidal drug release pattern 
(63,64).  
Lately, zinc ions have been adopted as crosslinking agent of interest. The zinc ion crosslinked 
pectin matrix releases drug at a lower rate than the calcium ion crosslinked sample (67,77,78). In 
comparison with calcium ions, zinc ions form a more extensive crosslink with pectin and reduce the 
degree of rehydration and molecular porosity of matrix to a greater extent. Rapid drug release from 
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calcium ion crosslinked matrix is presumably due to a greater level of solvent penetration into the 
calcium pectinate network followed by a greater propensity for ion exchange of calcium with 
sodium and potassium ions. The monovalent ions displace calcium ions from the gelled structure 
and transform insoluble calcium pectinate into soluble pectin which has less drug release retardation 
capacity.  
 
PECTIN-BASED COLON-SPECIFIC ORAL DRUG DELIVERY SYSTEM AND COLON 
CANCER  
Over the past five years, in vivo assessments indicate that colon-specific pectin-based oral dosage 
forms can be designed primarily through coating of drug matrix with pectin-ethylcellulose or 
Eudragit film (85,91). The early drug release in gastrointestinal tract is negated by coat 
hydrophobicity and reduced matrix solubility. The majority of drug is released or accumulated at 
the colonic region of intestinal tract. Pharmacokinetically, the propensity of drug absorption at 
colon can be low due to reduced absorption surface area and low drug permeability across colonic 
barrier. Some of the released drug may still be located in the colon lumen 24 hours after oral 
administration of matrix due to slow transit (85). Low drug absorption may be undesirable for 
systemically acting drugs. In colon cancer chemotherapy, low plasma drug concentration can 
nevertheless increase the safety margin of the treatment by lowering peak plasma drug levels and 
sustaining tumor exposure to the drug. Low plasma drug concentrations coupled to prolonged 
exposure to high local colonic drug concentration could facilitate DNA-directed action of the drug, 
which contributes to the anti-cancer effect.  
5-fluorouracil has been loaded into pectin microspheres by means of emulsion dehydration 
technique (91). Briefly, a w/o emulsion is first obtained by mixing the solution mixture of drug and 
pectin with isooctane. This is followed by dehydration of dispersed phase by acetone to produce the 
micropsheres. The formed microspheres, having a mean diameter between 25 and 30 μm, are then 
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coated with Eudragit S100 by an oil-in-oil solvent evaporation method. The coated microspheres 
are able to prevent the release of 5-fluorouracil at pH 1.2 and 4.5, otherwise observed for uncoated 
matrix. These microspheres can efficiently deliver drug to the colon after 6 to 8 hours of 
administration in rats. In another work reported by Wei et al. (85), 5-fluorouracil is encapsulated in 
pellets by means of extrusion-spheronization technique using microcrystalline cellulose as 
processing aid. The formed pellets are subsequently coated with pectin and ethylcellulose using the 
fluid-bed coating technique. In vivo bioavailability analysis of coated pellets indicates that a Tmax of 
14 h is obtainable when compared to uncoated samples which are characterized by a short Tmax of 
0.75 h. Formulation of 5-fluorouracil in these coated structures can delay the release of drug in 
gastrointestinal tract. 
 
Recent reports on pectin-based colonic delivery system containing 5-fluorouracil and methotrexate 
indicate that sustained-release pellets and microparticles are preferred as oral dosage form to deliver 
chemotherapeutic agents in colon cancer (80,84,85,91). Unlike gastric transit, small dosage forms 
show a slower colon transit than large dosage forms (1). Prolonged colonic retention of dosage form 
and/or consistent local colonic exposure to anti-cancer drug is more easily attainable by using 
multiple-unit particulate system such as beads, pellets and microparticles as drug delivery systems 
instead of single-unit tablets (often large because of high drug doses).  
 
Crosslinking agents have been part of the formulation for many pectin-based multi-particulate 
colon-specific drug delivery systems. In spite of recent reports favoring the use of zinc ions, 
calcium ions will possibly remain as the mainstream crosslinking agent as they promote pectinolytic 
enzymatic degradation of pectin and exhibits biological properties which aid to counteract the 
development of colon cancer. In a recent work of Chaurasia et al. (80), calcium pectinate beads in 
the size range of 20 to 30 μm are produced by modified emulsification method using calcium 
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chloride as crosslinking agent. These beads have a good encapsulation efficiency of methotrexate 
(up to 74 %) and release only 8 % of loaded drug when they are incubated for 5 h in simulated 
gastric fluid followed by enzymeless simulated intestinal fluid. The majority of drug release only 
when pectinase or cecal rat content is present in the simulated intestinal fluid, demonstrating that 
the pectinate matrix crosslinked by calcium ions is still an efficient carrier to target the release of 
anti-cancer drug at colon through exploiting the physiological features of colonic environment. 
 
The role of calcium in colon cancer has been evaluated in animals, epidemiologic studies and 
human intervention studies (97). Though there is no clear relationship between calcium intake and 
colon cancer development, dietary supplementation with calcium has been found to reduce 
adenoma size and number (18). High calcium and vitamin intake increases apoptosis of colonic 
epithelium and may reduce risk of colon cancer (16-18,98). The capability of calcium to combat 
colon cancer is likely ascribed by its binding affinity to potentially carcinogenic free bile acids in 
colon.  
 
Both pectin and calcium have indicated their biological significance in combating the development 
of colon cancer. The present review hitherto suggests that multi-particulate drug delivery system 
made of calcium pectinate can be an ideal carrier to orally administer and deliver chemotherapeutic 
agents to the colon for treatment of colon cancer, upon modification to prevent early drug release in 
the upper part of gastrointestinal tract. Both pectin and calcium should be the main excipients used 
in the formulation of the delivery system. These excipients can be used as matrix/coat substances. 
The success of chemotherapy is dependent on the ability of the delivery system to hinder premature 
drug release in the upper gastrointestinal tract, and be digested and released the loaded drug, 
possibly together with pectin and calcium at the site of disease. It is envisaged that the 
reproducibility of matrix/coat digestion and drug release at colon is an interplay effect of colonic 
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pH and microflora environment with the physicochemical properties of drug, pectin and other 
excipients of the dosage form. The composition of every individual microflora can fluctuate under 
illness and to a lesser extent be induced by dietary intervention (99). High risk of colon cancer is 
associated with the presence of Bacteroides vulgatus and Bacteroides stercosis in human. However, 
the exact complications brought about by microflora changes in presence of colon cancer on the 
performance of pectin-based drug delivery systems are not known and likely to remain elusive. One 
main reason for this is that the intestinal bacteria are adapted to an anaerobic environment (100). 
They are difficult or impossible to culture extra-intestinally for study. With the advent of genetic 
technology, only 1822 of more than 20000 rRNA gene sequences in GenBank are in fact 
documented as derived from human gastrointestinal tract, and 1689 are uncultured bacteria. Another 
issue is related to pH differences. The colonic mucosa pH is alkaline (pH = 8) and is similar on both 
sides of colon in healthy and colon cancer patients (101,102). Both healthy right colostomates and 
cancer patients have the same luminal pH at 7.6, but the fecal pH of healthy right colostomates is 
lower than that of colon cancer patients (pH = 6.6) (101). Variations in rate and extent of drug 
release from pectin-based dosage forms are deemed to be induced by different fecal pH 
environments at the proximal colon in diseased and healing states, and such variations are expected 
to be complicated by and/or be a resultant effect of concomitant changes of microflora composition 




Continuing efforts to design pectin-based delayed-release dosage form for use in colonic drug 
delivery are undertaken by many researchers. Gelatin, alginate and xyloglucan are some polymers 
explored in formulation of pectin-based drug delivery system (103-106). The pectin-based dosage 
form has been recently subjected to treatment by microwave to evaluate the capacity of radiation to 
  23 
further reduce the drug release propensity of matrix at upper gastrointestinal tract (107,108). 
Ongoing research is conducted to produce water-resistant pectin derivatives without compromising 
their susceptibility to microflora fermentation in the colon (36). Pectin receives an overwhelming 
attention on its practical applications and implications in drug delivery. Nonetheless, one shall 
highlight that there is no clear picture on the exact complex structure of pectin and the 
physicochemical attributes of pectin vary with its source and manufacturing process (37,56). 
Further work shall be conducted to characterize the physicochemical attributes of pectin and 
evaluate its structure-activity relationship with reference to colon-specific drug delivery. Pectin has 
shown an indication to be able to suppress colon cancer growth lately. The collective effectiveness 
of pectin as drug delivery vehicle, drug and/or therapeutic enhancer in colon-specific delivery of 
anti-cancer drugs requires verification. The distribution probability of cancer varies from one site to 
another site of colonand 99% of carcinomas occur singly (Fig. 1) (21). The possibility of pectin-
based colon-specific dosage form to perform solely and precisely at a cancer site of an abnormal 
colon is a fascinating challenge for future pharmaceutists. Polymers, other than pectin, require 
further investigation on their potential use as concurrent drug carrier and chemotherapeutic agent 
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Table 1. Types of pectin-based colon-specific oral drug delivery system. 
 
No. Type of dosage 
form 
Type of drug Type of 
pectin 
Formulation mechanism Reference 












Mixing of pectin with varying 







Use of calcium pectinate as matrix 







Mixture of pectin, HPMC and 
calcium salt as matrix substance of 
tablet. 
66 






Ionotropic gelation of pectin with 
zinc ions into microparticles 
followed by compression of dry 
microparticles into tablet with 
dextran. 
67 




Samaium oxide 152 - Tablet made of calcium pectinate and 
pectin is enteric coated by Eudragit L 
to target isotope release at ascending 
colon.  
68 




Samaium oxide 152 - Tablet made of calcium pectinate and 
guar gum is enteric coated by 
Eudragit L to target isotope release at 
ascending and transverse colon. 
68 









Drug core consists of pectin and 
ethylcellulose and is coated with 
Eudragit L100. 
69 
8. Pectin coated 
tablet 




Pectin as compression coat onto drug 
core. 
70 






Mixture of pectin and high molecular 
weight 
hydroxypropylmethylcellulose 
(HPMC) as compression coat onto 









Mixture of pectin, chitosan and 





Paracetamol  Pectin 
USP 
Mixing of pectin with hydrophobic 










Pectin-chitosan as inter-polymer 




 Multiple-unit     






Ionotropic gelation of pectin with 
zinc ions in low pH aqueous medium 
to form beads. Low pH reaction 
medium promotes protonation of 
carboxylate moiety of pectin, 
suppresses intermolecular charge-
charge repulsion, reduces polymer 
77,78 
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chain solubility and facilitates 
polymer conformational ordering. 
Beads are subsequently introduced in 
enteric coated capsule. 






Ionotropic gelation of pectin with 












Ionotropic gelation of pectin with 





Methotrexate - Ionotropic gelation of pectin with 










Coacervation/crosslinking of pectin 
with chitosan and calcium ions in a 










Coacervation/crosslinking of pectin 
with chitosan and calcium ions in a 







Immersion coating of calcium 









Mixing of pectin with hydrophobic 








Pectin-Eudragit RL30D as inter-


















Coating of pellets with Aquacoat 
ECD30, Surelease and Eudragit 
NE30D, RS30D containing high 
methoxyl pectin or low methoxyl 
calcium pectinate. 
87 










Crosslinking of pectin with calcium 
ions into microparticles followed by 
Eudragit S100 coating onto 
microparticles by immersion-solvent 
evaporation technique. 
88 








Crosslinking of pectin with calcium 
ions into beads followed by Eudragit 
S100 coating onto beads. 
89,90 
13. Eudragit S100 
coated pectin 
microparticles 
5-fluorouracil - Pectin microparticles are formed by 
emulsion dehydration technique and 
subsequently coated by Eudragit 
S100 via oil-in-oil solvent 
evaporation method. 
91 




Brilliant Blue G 






HM pectin as coat onto LM pectinate 
core. 
92 
  37 






























































  38 
List of Figures 
 
Figure 1. Gastrointestinal tract and its distribution probability of colon cancer. 
Figure 2. Development of colon cancer by chromosomal and microsatellite instability 
pathways. 
Figure 3. Modulation of galectin-3 mediated colon cancer development by pectin. 
Figure 4. Formulation and design of microflora triggered pectin-based colon-specific oral drug 
delivery system.  
Figure 5. Schematic flow of processing technology employed in design of pectin-based colon-




Mixing of pectin or pectin complex and drug 
with crosslinker and/or other excipients using a 
shaker mixer at solid state 
↓ 
Granulation of solid powder mixture by 
binding liquid in planetary mixer or mortar 
↓ 
Sieving of wet mass 
↓ 
Drying of sieved mass 
↓ 
Sieving of dry granules 
↓ 
Lubrication of dry granules 
↓ 
Compression of granules into tablet by single-
punch tableting machine or rotary press 
↓ 
Matrix tablet coating with pectin and/or other 
polymers or inter-polymer complex admixed 
with plasticiser and anti-adherent 
 -Pan coating 
 -Drum coating 
 -Fluid-bed spray coating 
 -Compression coating 
↓ 









Mixing of pectin, drug, crosslinker and extrusion aids using a 
planetary mixer at solid state 
↓ 
Wetting of solid powder mixture by binding liquid 
↓ 
Extrusion of wet mass using a extruder 
↓ 
Rounding of extrudates using a spheronizer 
↓ 
Drying of spheroids 
↓ 
Coating of spheroids with pectin, inter-polymer complex and/or 
other polymers admixed with plasticiser and anti-adherent 
 -Fluid-bed spray coating 
 -Immersion coating via crosslinking, coecervation 
 and dehydration processes 
↓ 
Drying of coated matrix 
 
Beads/Microparticles 
Mixing of pectin and drug in the form of solution 
or dispersion 
↓ 
Extrusion of mixture in the form of liquid 
droplets into crosslinking or coacervating liquid 
medium 
↓ 
Crosslinking, coacervation and curing of matrix 
↓ 
Filtration of matrix beads or microparticles 
↓ 
Washing of matrix 
↓ 
Drying of matrix 
↓ 
Coating of matrix 
 
-Matrix wetting by polymeric coating solution 
followed by filtration, washing and drying of 
coated matrix 
-Salting out of coating polymer onto the surfaces 
of matrix through its interaction with electrolyte 
pre-coated onto the matrix 
-Immersion of matrix in polymeric coating 
solution followed by solvent-evaporation using 
rotary evaporator technique 
Microparticles 
Dispersion of pectin-drug solution in an organic phase with 
surfactant into an emulsion 
↓ 
Rapid cooling of emulsion 
↓ 
Dehydration of dispersed pectin phase of emulsion by 
acetone 
↓ 
Solvent evaporation of emulsion 
↓ 
Freeze-drying of matrix microparticles 
↓ 
Polymeric coating of dried matrix by oil-in-oil solvent 
evaporation method 
↓ 
Washing of coated matrix 
↓ 
Drying of coated matrix 
Figure 5. Schematic flow of processing technology employed in design of pectin-based 
colon-specific oral drug delivery system.  






